3 ASX 200 healthcare stocks that could deliver big returns for investors

Analysts see a lot of value in these stocks at current levels.

| More on:
A doctor appears shocked as he looks through binoculars on a blue background.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There could be some big returns on offer in the healthcare sector for Australian investors according to analysts.

For example, the three ASX 200 healthcare stocks listed below have all been named as buys by analysts and tipped to deliver double-digits from current levels.

Here's what they are saying about them:


The first ASX 200 healthcare stock that could be a buy is CSL. It is the biotechnology giant behind the CSL Behring plasma therapies business, the CSL Seqirus vaccines business, and the CSL Vifor iron deficiency and nephrology business.

Macquarie is feeling very bullish about the company due to the positive medium-term outlook for CSL Behring's immunoglobulins. As a result, earlier this week, it upgraded the company's shares to an outperform rating with an improved price target of $330.00. This implies a potential upside of 17% for investors over the next 12 months.

But its shares may not stop there. It is also worth noting that Macquarie sees scope for CSL's shares to rise beyond $500 within three years.

ResMed Inc. (ASX: RMD)

Over at Morgans, its analysts think that ResMed would be a great option for investors looking for healthcare exposure. ResMed is the global leader in sleep disorder treatment solutions.

This is a great area of the market to be in given the huge addressable market. It has previously been estimated that 1 in 5 people suffer from sleep apnoea. However, the vast majority of these sufferers are undiagnosed. This gives ResMed a huge growth runway even with the emergence of weight loss wonder drugs.

In fact, Morgans' analysts recently stated that they "see these products having little impact on the large, underserved sleep disorder breathing market, and do not view them as category killers."

Morgans has an add rating and a $32.82 price target on its shares. This suggests a potential upside of 13% for investors.

Telix Pharmaceuticals Ltd (ASX: TLX)

Finally, the team at Bell Potter think that Telix could be an ASX 200 healthcare stock to buy. It is the radiopharmaceutical company behind the increasingly popular Illuccix prostate cancer imaging agent.

Its analysts believe Telix is well-positioned for growth over the coming years and are forecasting revenue increasing from $502.5 million in FY 2023 to $993.7 million in FY 2026. The broker is also expecting its EBITDA to grow at an even quicker rate. It has pencilled in EBITDA of $211.1 million in FY 2026, which compares favourably to FY 2023's EBITDA of $58.4 million.

This morning, the broker reiterated its buy rating and $14.50 price target on the company's shares. This implies a potential upside of approximately 13% from where its shares trade today.

Motley Fool contributor James Mickleboro has positions in CSL, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended CSL, Macquarie Group, ResMed, and Telix Pharmaceuticals. The Motley Fool Australia has positions in and has recommended Macquarie Group and ResMed. The Motley Fool Australia has recommended CSL and Telix Pharmaceuticals. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Research, collaboration and doctors working digital tablet, analysis and discussion of innovation cancer treatment. Healthcare, teamwork and planning by experts sharing idea and strategy for surgery.
Healthcare Shares

Buy, hold or sell these 3 ASX 200 healthcare shares: Experts

These experts reveal their calls on CSL, Resmed and Sonic Healthcare shares today.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Share Gainers

Guess which ASX healthcare stock just exploded 63% on Federal budget funding news!

Investors are bidding up the ASX healthcare stock amid extra funding in the Federal budget.

Read more »

two doctors smile as they sit together at a desk looking at a patient's Xray.
Healthcare Shares

This ASX 200 healthcare stock just hit an all-time high: Is it too late to buy?

The valuation of this high-performer has soared.

Read more »

A smiling woman sits in a cafe reading a story on her phone about Rio Tinto and drinking a coffee with a laptop open in front of her.
Healthcare Shares

1 magnificent ASX stock down 10% to buy and hold forever

Analysts say this high-quality stock is a great option for investors right now.

Read more »

ventilator mask
Healthcare Shares

3 reasons ResMed shares 'are just too cheap!'

This stock could still produce healthy gains, according to one fund manager.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX healthcare shares rocking higher on big news

This 'spray-on skin' company and cancer-fighting biotech have exciting news for shareholders today.

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

Insider still buying Mesoblast shares despite 230% rise this year: Should you buy?

This high-flying share is still reporting insider buying. Should you buy too?

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Buy CSL shares for growing dividends and 'compelling long-term tailwinds'

CSL has increased both its interim and final dividend every year since 2021.

Read more »